CONMED (CNMD) Hisse Özeti
Bir tıbbi teknoloji şirketi olan CONMED Corporation, cerrahi prosedürler için cihazlar ve ekipmanlar geliştirmekte, üretmekte ve satmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 5/6 |
| Gelecekteki Büyüme | 3/6 |
| Geçmiş Performans | 1/6 |
| Finansal Sağlık | 4/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
CNMD Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CONMED Corporation Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$36.80 |
| 52 Haftanın En Yüksek Seviyesi | US$61.08 |
| 52 Haftanın En Düşük Seviyesi | US$33.21 |
| Beta | 0.99 |
| 1 Aylık Değişim | 5.78% |
| 3 Aylık Değişim | -6.15% |
| 1 Yıllık Değişim | -36.20% |
| 3 Yıllık Değişim | -70.64% |
| 5 Yıllık Değişim | -74.38% |
| Halka arzdan bu yana değişim | 1,740.00% |
Son Haberler & Güncellemeler
CNMD: Execution Repairs And Margin Stability Will Support Future Upside
Narrative Update Overview Analysts have trimmed their average price targets on CONMED by $3, alongside neutral ratings and concerns around product execution and a lack of near term catalysts, even as updated assumptions reflect steady revenue growth, profit margins around 10.8% and a slightly lower future P/E multiple. Analyst Commentary Recent research on CONMED has centered on valuation reset, execution around key products, and the search for clear catalysts, with JPMorgan trimming its price target by $3 and other firms shifting to more neutral stances.
CNMD: Execution Questions And Limited Catalysts Will Shape Balanced Risk Profile
Analysts have reset their price target on CONMED to $39, trimming it by $16 from the prior $55. They cite concerns around AirSeal competition, recent execution issues, and a lack of clear near term catalysts for a turnaround in sentiment.Recent updates
CNMD: Execution Repairs And Margin Stability Will Support Future Upside
Narrative Update Overview Analysts have trimmed their average price targets on CONMED by $3, alongside neutral ratings and concerns around product execution and a lack of near term catalysts, even as updated assumptions reflect steady revenue growth, profit margins around 10.8% and a slightly lower future P/E multiple. Analyst Commentary Recent research on CONMED has centered on valuation reset, execution around key products, and the search for clear catalysts, with JPMorgan trimming its price target by $3 and other firms shifting to more neutral stances.CNMD: Execution Questions And Limited Catalysts Will Shape Balanced Risk Profile
Analysts have reset their price target on CONMED to $39, trimming it by $16 from the prior $55. They cite concerns around AirSeal competition, recent execution issues, and a lack of clear near term catalysts for a turnaround in sentiment.CNMD: Execution Rebound And Margin Focus Will Support Future Upside
The analyst price target for CONMED has been reduced by $3 to $52, as analysts factor in a slightly higher discount rate and a lower future P/E multiple while still modeling modestly higher revenue growth and profit margins, and acknowledging recent downgrades that highlight concerns around execution and a lack of near term catalysts. Analyst Commentary Recent research on CONMED reflects a mixed setup, with some analysts focused on execution risks and a lack of clear near term catalysts, while others maintain a more balanced stance that supports a mid range valuation and steady expectations.CNMD: Execution Concerns And Leadership Transition Will Shape Balanced Risk Profile
Narrative Update: CONMED Price Target Shift The analyst price target for CONMED has been revised from $42 to $39, with analysts pointing to execution missteps, weaker sentiment around the AirSeal product, and a lack of clear near term catalysts as key reasons for the adjustment. Analyst Commentary Recent Street research on CONMED has tilted more cautious, with several bearish analysts highlighting execution risk, questions around AirSeal, and a limited near term catalyst path to re-rate the shares.CNMD: Portfolio Refocus And Leadership Change Will Shape Balanced Risk Profile
Narrative Update on CONMED Analysts kept their $42 price target for CONMED unchanged. They cited slightly higher assumed revenue growth and profit margins along with a modestly lower discount rate and future P/E, which together support a steady valuation view despite ongoing sector volatility highlighted in recent research.CNMD: Portfolio Refocus And Higher Future P/E Will Support Returns
Analysts maintained their fair value estimate for CONMED at $55.00 and refreshed their price target framework to incorporate more conservative assumptions for revenue growth and profit margins, while also reflecting a higher future P/E multiple. Analyst Commentary Bullish analysts appear comfortable holding their US$55.00 fair value estimate for CONMED while updating models to reflect more conservative assumptions for revenue growth and margins.CNMD: Future Portfolio Shift And Capital Moves Signal Balanced Risk Profile
Analysts have reduced their price target on CONMED to US$42 from US$55, citing a higher discount rate, more conservative revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple in their updated models. Analyst Commentary Bearish analysts are using the lower US$42 price target as a signal that they see less room for upside in CONMED at current levels, especially when they factor in higher discount rates and more cautious revenue assumptions.
CNMD: Gastro Exit And Buybacks Will Support Future Margin Expansion
Analysts modestly adjusted their price target for CONMED, citing a slightly lower discount rate, unchanged fair value of $48.40, and minimal tweaks to long term growth and P/E assumptions that together fine tune their outlook rather than overhaul it. Analyst Commentary Bullish Takeaways Bullish analysts see the steady fair value estimate of $48.40, together with the slightly lower discount rate, as a sign that their view on CONMED’s risk profile and long term earnings power remains intact even after recent fine tuning.CNMD: Gastro Exit And Buybacks Will Support Margin Expansion Ahead
Analysts have trimmed their price target for CONMED to about US$48.40 from roughly US$54.00, pointing to slightly lower growth assumptions and a reduced future P/E multiple, partly balanced by a marginally higher profit margin outlook. What's in the News CONMED plans to exit its gastroenterology product lines, aiming to focus resources on core areas such as minimally invasive, robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair (Key Developments).CNMD: Focused Surgical Portfolio And Buybacks Will Support Stronger Future Returns
Analysts have lowered their price target on CONMED from 80.00 dollars to 55.00 dollars, citing slightly slower expected revenue growth and a higher discount rate that more than offset improved margin and valuation assumptions. What's in the News CONMED will exit its gastroenterology product lines to focus resources on core areas including minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair.Conmed Taking On More Pain In The Pursuit Of Future Gain
Dec 15CNMD: Margin Expansion And Buyback Program Will Drive Strong Future Returns
Analysts have nudged their price target on CONMED slightly higher to $54, citing modestly lower discount rate and revenue growth assumptions, offset by a slightly improved profit margin outlook and a marginally lower future P/E multiple that together support a stable valuation profile. Analyst Commentary Analyst views on CONMED remain balanced, with recent model tweaks reflecting a more nuanced outlook on growth, profitability, and valuation.CNMD: Margin Initiatives And Robust Buyback Will Drive Long-Term Shareholder Value
CONMED's analyst price target has been reduced from $56 to $54 per share, as analysts cite modest cuts to growth and profit outlooks, along with slightly higher discount rates following recent sector updates. Analyst Commentary Analysts have provided a range of perspectives on CONMED’s outlook based on recent developments in company performance and sector trends.CNMD: Improving Profit Margins And Robust Buyback Program Will Drive Shareholder Value
CONMED's analyst price target has been lowered from $61 to $56. This change reflects a more cautious stance as analysts point to expectations of slower revenue growth and a higher discount rate, despite improvements in underlying profit margins and future valuation multiples.These 4 Measures Indicate That CONMED (NYSE:CNMD) Is Using Debt Reasonably Well
Oct 06
CONMED (NYSE:CNMD) Has Announced A Dividend Of $0.20
Sep 12CONMED's (NYSE:CNMD) Solid Profits Have Weak Fundamentals
Aug 08Are Investors Undervaluing CONMED Corporation (NYSE:CNMD) By 49%?
Jul 03CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20
May 24CONMED Corporation's (NYSE:CNMD) Shares Bounce 26% But Its Business Still Trails The Market
May 17Is CONMED (NYSE:CNMD) Using Too Much Debt?
Mar 31Repeated Disappointments On Growth And Margins Leaves Conmed Even Deeper In The Doghouse
Feb 28CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20
Feb 28CONMED Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 08CONMED Corporation (NYSE:CNMD) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 20Is Now The Time To Look At Buying CONMED Corporation (NYSE:CNMD)?
Jan 01CONMED (NYSE:CNMD) Has Affirmed Its Dividend Of $0.20
Dec 13Does CONMED (NYSE:CNMD) Have A Healthy Balance Sheet?
Nov 25CONMED's (NYSE:CNMD) Earnings Are Weaker Than They Seem
Nov 07Earnings Beat: CONMED Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 02Should You Investigate CONMED Corporation (NYSE:CNMD) At US$71.92?
Oct 01Hissedar Getirileri
| CNMD | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | -4.0% | -4.2% | 0.8% |
| 1Y | -36.2% | -18.5% | 27.8% |
Getiri vs. Endüstri: CNMD geçen yıl % -18.5 oranında getiri sağlayan US Medical Equipment sektörünün gerisinde kaldı.
Getiri vs Piyasa: CNMD geçen yıl % 27.8 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| CNMD volatility | |
|---|---|
| CNMD Average Weekly Movement | 5.6% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: CNMD son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: CNMD 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1970 | 3,900 | Pat Beyer | www.conmed.com |
Bir tıbbi teknoloji şirketi olan CONMED Corporation, cerrahi prosedürler için cihazlar ve ekipmanlar geliştirmekte, üretmekte ve satmaktadır. Şirket, ortopedik cerrahlara yumuşak doku yaralanmalarının güçlendirilmesi ve onarımı için klinik çözümler sunan BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors ve Agro Knotless Suture Anchors gibi ortopedik cerrahi ürünlerinin yanı sıra, cerrahların minimal invaziv spor hekimliği ameliyatları gerçekleştirmesini sağlayan elektrikli rezeksiyon aletleri, sıvı yönetimi ve görselleştirme sistemleri ve ilgili tek kullanımlık ürünleri içeren destekleyici ürünler sunmaktadır. Ayrıca Hall surgical markası altında ortopedik, artroskopik, oral/maksillofasiyal, podiatrik, spinal ve kardiyotorasik ameliyatlarda kullanılmak üzere pille çalışan, otoklavlanabilir, büyük ve küçük kemik elektrikli alet sistemleri sunmaktadır.
CONMED Corporation Temel Bilgiler Özeti
| CNMD temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$1.11b |
| Kazançlar(TTM) | US$54.85m |
| Gelir(TTM) | US$1.37b |
CNMD aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| CNMD gelir tablosu (TTM) | |
|---|---|
| Gelir | US$1.37b |
| Gelir Maliyeti | US$624.24m |
| Brüt Kâr | US$746.27m |
| Diğer Giderler | US$691.42m |
| Kazançlar | US$54.85m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 1.82 |
| Brüt Marj | 54.45% |
| Net Kâr Marjı | 4.00% |
| Borç/Özkaynak Oranı | 80.7% |
CNMD uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/03 21:09 |
| Gün Sonu Hisse Fiyatı | 2026/05/01 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
CONMED Corporation 16 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Travis Steed | Barclays |
| Travis Steed | BofA Global Research |
| Travis Steed | BofA Global Research |